Evidence map›Paper›PMID 32582815›Full record

ArticleInternational journal of particle therapy2020

Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma.

Bradford S Hoppe, Raymond B Mailhot Vega, Nancy P Mendenhall, Eric S Sandler, William B Slayton, Howard Katzenstein, Michael J Joyce, Zuofeng Li, Stella Flampouri

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of particle therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Bradford S HoppeDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.
Raymond B Mailhot VegaDepartment of Radiation Oncology, University of Florida, Jacksonville, FL, USA.
Nancy P MendenhallDepartment of Radiation Oncology, University of Florida, Jacksonville, FL, USA.
Eric S SandlerDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Nemours Children's Specialty Care, Jacksonville, FL, USA.
William B SlaytonDepartment of Pediatric Hematology/Oncology, University of Florida, Gainesville, FL, USA.
Howard KatzensteinDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Nemours Children's Specialty Care, Jacksonville, FL, USA.
Michael J JoyceDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Nemours Children's Specialty Care, Jacksonville, FL, USA.
Zuofeng LiDepartment of Radiation Oncology, University of Florida, Jacksonville, FL, USA.
Stella FlampouriDepartment of Radiation Oncology, Emory University, Atlanta, GA, USA.
University of Florida · USNemours Children’s Clinic · USEmory University · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLocal relapse is a predominant form of recurrence among pediatric patients with Hodgkin lymphoma (PHL). Although PHL radiotherapy doses have been approximately 20 Gy, adults with Hodgkin lymphoma receiving 30 to 36 Gy experience fewer in-field relapses. We investigated the dosimetric effect of such a dose escalation to the organs at risk (OARs). MATERIALS AND

methodsTen patients with PHL treated with proton therapy to 21 Gy involved-site radiation therapy (ISRT

resultsThe ISRT

conclusionBoosting the postchemotherapy residual target dose to 30Gy can allow for dose escalation with a slight OAR dose increase. Treating the residual disease for the full 30Gy, however, would reduce the OAR dose significantly compared with ISRT

Indexed as

dose escalationHodgkin lymphomaorgans at riskpediatric lymphoma

Identifiers

PMID32582815
PMCPMC7302731
OpenAlexW3018249247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.